OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.
High growth potential with mediocre balance sheet.
Share Price & News
How has OptiNose's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 0OP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 0OP underperformed the German Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: 0OP underperformed the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is OptiNose's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is OptiNose undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 0OP (€7.1) is trading below our estimate of fair value (€87.1)
Significantly Below Fair Value: 0OP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 0OP is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: 0OP is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 0OP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 0OP is overvalued based on its PB Ratio (7x) compared to the DE Pharmaceuticals industry average (2.3x).
How is OptiNose forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0OP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: 0OP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0OP's is expected to become profitable in the next 3 years.
Revenue vs Market: 0OP's revenue (41.4% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 0OP's revenue (41.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0OP's Return on Equity is forecast to be high in 3 years time
How has OptiNose performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 0OP is currently unprofitable.
Growing Profit Margin: 0OP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 0OP is unprofitable, and losses have increased over the past 5 years at a rate of -45.7% per year.
Accelerating Growth: Unable to compare 0OP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0OP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.3%).
Return on Equity
High ROE: 0OP has a negative Return on Equity (-250.32%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is OptiNose's financial position?
Financial Position Analysis
Short Term Liabilities: 0OP's short term assets ($144.1M) exceed its short term liabilities ($30.0M).
Long Term Liabilities: 0OP's short term assets ($144.1M) exceed its long term liabilities ($74.9M).
Debt to Equity History and Analysis
Debt Level: 0OP's debt to equity ratio (166.8%) is considered high.
Reducing Debt: Insufficient data to determine if 0OP's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 0OP has a low level of unsold assets or inventory.
Debt Coverage by Assets: 0OP's debt is covered by short term assets (assets are 1.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0OP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0OP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is OptiNose's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 0OP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 0OP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 0OP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 0OP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 0OP's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Miller (58yo)
Mr. Peter K. Miller has been the Chief Executive Officer of OptiNose US Inc., since 2010. Mr. Miller has been the Chief Executive Officer at Optinose, Inc. since 2010. He serves as the Chief Executive Offi ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD778.60K) is about average for companies of similar size in the German market ($USD802.74K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
|CEO & Director||10.1yrs||US$778.60k||0.29% $910.0k|
|President & COO||10.1yrs||US$609.00k||0.12% $381.9k|
|Chief Financial Officer||3.1yrs||US$486.67k||0.015% $46.4k|
|Chief Legal Officer & Corporate Secretary||3.1yrs||US$510.50k||0.016% $49.1k|
|Vice President of Investor Relations & Business Operations||0yrs||no data||no data|
|Vice President of Human Resources||2yrs||no data||no data|
|Senior Vice President of Clinical Development & Medical Affairs||2.3yrs||no data||no data|
|Chief Commercial Officer||0yrs||no data||no data|
|Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)||0yrs||no data||no data|
Experienced Management: 0OP's management team is considered experienced (3.1 years average tenure).
|CEO & Director||10.1yrs||US$778.60k||0.29% $910.0k|
|Non-Management Director||10.1yrs||US$252.01k||0.041% $129.1k|
|Chairman of the Board||2.3yrs||US$295.93k||0.027% $86.0k|
|Independent Director||2yrs||US$597.62k||no data|
|Independent Director||10.1yrs||US$267.01k||no data|
|Non-Management Director||2.9yrs||US$257.01k||no data|
|Independent Director||2.3yrs||US$263.71k||no data|
|Independent Director||1.7yrs||US$448.69k||0.0044% $13.7k|
Experienced Board: 0OP's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 0OP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.
OptiNose, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: OptiNose, Inc.
- Ticker: 0OP
- Exchange: DB
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$341.979m
- Listing Market Cap: US$314.826m
- Shares outstanding: 45.84m
- Website: https://www.optinose.com
Number of Employees
- OptiNose, Inc.
- 1020 Stony Hill Road
- Suite 300
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OPTN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2017|
|0OP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2017|
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 23:01|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.